Press Release

RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

NeoGenomics Reports Third Quarter 2022 Results

NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors

NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022

NeoGenomics Lab Operations | Hurricane Ian Update

NeoGenomics Hurricane Ian Emergency Response

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients